Author: Ryan Allway

VANCOUVER, British Columbia, March 22, 2018 (GLOBE NEWSWIRE) — Quadron Cannatech Corporation (the “Company” or “Quadron”) (CSE:QCC) is pleased to announce that is has completed the sale of two BOSS CO2 Extraction System (“BOSS”) to an authorized grower located in the Fraser Valley, British Columbia.

With the overwhelming interest in the BOSS from the recent MJBiz Conference in Vegas and the Lift Expo in Vancouver, interested buyers have been investigating and analyzing the BOSS compared to other available CO2 extraction systems on the market.

“Quadron is well capitalized following the recent equity raises, along with the exercise of warrants,” stated Rosy Mondin, CEO of Quadron.  “We have enough capital to not only service the existing demand for the BOSS from interested parties, but also the capital to proceed with the development of new equipment.  2018 will be a milestone year for Quadron.”

The BOSS CO2 Extraction System combines proprietary max flow technology with advanced thermodynamics, automated features and an exclusive plug and play design.  The BOSS has a very small footprint, requiring only a fraction of the space and energy requirements compared to other systems on the market.  Installation is simple – no external hardware of facility renovations required. All that is needed are two electrical outlets and an hour to set-up.

THE BOSS EXTRACTION SYSTEM ADVANTAGES

• Automated system with remote monitoring and control features
• Software collects, stores, and analyzes data for Research & Development
• Programmable cycles – maximizing extraction and separation efficiency
• Plug and Play self-contained system with no external setup required
• Simplified assembly with only two pieces of equipment to set-up, two plugs and four hoses to connect
• Integrated heat exchanger with proprietary advanced thermodynamics
• High precision operating parameters for accurate performance
• Ability to collect extract during runtime

Click here to view more information on the BOSS CO2 Extraction System.

According to a Mackie Research Capital Corp. report, which assumes full legalization (medical and recreational) in 2018, the growth of cannabis oil consumption in Canada is expected to grow from 284 litres in 2015 to 562,613 litres by 2020 (198,000-per-cent growth) versus dried marijuana consumption of 6,388 kilograms in 2015 to 110,034 kilograms in 2020 (1,600-per-cent growth).

Quadron: Quadron focuses on ancillary equipment, products and services for the authorized cannabis industry by providing a full array of end-to-end extraction and processing solutions including sales of end user delivery options (such as vapor pens) for recreational and medical consumers.

For more information, visit: www.quadroncannatech.com

On behalf of the Board of Directors of
QUADRON CANNATECH CORPORATION

Rosy Mondin, CEO
rosy@quadroncannatech.com

Investor Relations Contact:
KIN Communications Inc.
Caleb Jeffries, VP, Investor Relations
1-866-684-6730
QCC@kincommunications.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, including with respect to the scheduled closing date of the Offering and the intended use of the proceeds of the Offering, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”.  Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.

The post Quadron Cannatech Secures Sale of Two “BOSS” CO2 Extraction Systems appeared first on CannabisFN.

VANCOUVER, British Columbia, March 21, 2018 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) (RVVQF) (1IT.F) is pleased to announce that it has commenced trading on the Frankfurt Stock Exchange with immediate effect.  RavenQuest’s common shares commenced trading under the symbol “1IT”.

RavenQuest CEO, George Robinson, stated that “trading on the Frankfurt Exchange gives our capital markets exposure to a truly global reach, providing ease of access, transparency and peace of mind for European and international investors.  Truly global companies have a presence in Europe and we are very excited for our company to have this listing.”

“The Cannabis Act federally legalizes the adult recreational use of cannabis in Canada.  Having passed through the House of Commons, the bill is now in the final stages of the legislative process.  Canada’s cannabis-friendly investment climate is a unique opportunity in this rapidly growing segment of the global economy, and RavenQuest is an even more unique company within the Canadian cannabis sector.  Our focus upon Indigenous communities, our game-changing grow technology, our plant optimization science and our management services all allow for diversified revenue streams and tremendous growth potential.  We welcome every opportunity to share our story with the world, and a Frankfurt listing is a big step in that direction,” Robinson continued.

RavenQuest will continue to trade on the Canadian Securities Exchange (CSE) under the symbol “RQB” and the OTCQB under the symbol “RVVQF”.

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services and consulting, and specialized research and development.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications 604-484-1230

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws.  The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes.  By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

The post RavenQuest Begins Trading on Frankfurt Exchange Under Symbol “1IT” appeared first on CannabisFN.

Calgary, Alberta (FSCwire) – International Cannabrands Inc. (CSE:JUJU.A; FSE:31G; US OTC:GEATF) (the “Company”) announces it has entered into a Social Media Agreement with Bang Digital Media Inc., a wholly owned subsidiary of Bang Holdings Corp (OTC: BXNG), who will provide digital strategy, content creation and social media management services specifically to the JuJu Royal™ brand.

The Company licenses its cannabis brand to growers, edible manufacturers, oil extractors and the producers of ancillary products, apparel and merchandising both in the United States and internationally.

The company works closely with Julian Marley, son of legendary musician Bob Marley, in the marketing of his proprietary brand, JuJu Royal Ultra Premium Cannabis. As a brand, JuJu Royal (Julian Marley’s nickname) includes the signature cannabis strains; “JuJu OG,” “Lions Domain,” “Jungle Cheese” and “Heavenly Heights.”

“Julian Marley is a deeply spiritual man and a devout Rastafari. Therefore, it was important for us to find a partner who respects the Rastafarian culture,” Travis Belcher, President and COO of the Company said. “We believe that Bang Digital Media is the perfect fit as they have a deep understanding of cannabis use as a sacrament. Further, they approach their business in a way that reflects the true values of Julian Marley and the JuJu Royal brand.”

Bang Digital Media’s extensive experience in building and engaging both cannabis and spiritual communities was a leading factor in the Company’s decision to engage Bang Digital Media.

“We are extremely excited to work with International Cannabrands, Mr. Marley and the JuJu Royal brand,” Steve Berke, CEO of Bang Digital Media said. “Our team has a proven track record of building and aggregating audiences of cannabis consumers. We have also been instrumental in developing the online presence of the International Church of Cannabis in Denver – proving we are able to succeed at the nexus of religion and cannabusiness.”
About Bang Holdings Corporation

Bang Holdings Corporation (OTCQB: BXNG), through its subsidiary Bang Digital Media, innovates and utilizes new Advertising-Technologies to help cannabis brands connect to cannabis consumers. Through their original content, digital channels, and influencer-based marketing platform, Bang Digital Media enables cannabis brands to bypass a restrictive mainstream advertising system to reach cannabis consumers directly. For more information, please visit www.bangdigitalmedia.com.
About International Cannabrands Ltd.

International Cannabrands acquired the exclusive rights to Julian Marley’s JuJu Royal™ brand to educate people about the natural connection between Julian Marley, Rastafarian culture, reggae music, and marijuana. International Cannabrands generates revenue from licensing brands to growers, edible manufacturers, oil extractors, producers of ancillary products and apparel in the United States where cannabis has been legalized at the state level, as well as products containing CBD in the US and internationally. Select JuJu Royal products are available in California, Washington, Colorado and Puerto Rico with CBD-only products available in the U.K., the birthplace of Julian Marley. The Company is looking to expand JuJu Royal into Nevada in the near future. The company was founded in 2014 and is based out of Denver, Colorado. The Company believes as the market becomes saturated with products varying in potency and quality, that the branded products will rise to the top and the Company intends to exploit all opportunities available to realize the full value of the Julian Marley brand and to attract other brands.

About JuJu Royal

Julian Marley conveys his message of legalization, freedom, and love through the JuJu Royal brand, a line of naturally produced medicinal herbs using the best solventless technology. One percent of proceeds are distributed for the benefit of veterans using cannabis through the Weed for Warriors Project. More information about the brand and various products can be obtained at www.jujuroyal.net. International Cannabrands Ltd is continuing to work with Julian Marley to identify and develop future strains of marijuana that meet Julian’s exacting standards. The Company is continuing to conduct research and development with certain origin genetics to produce additional signature Julian Marley strains for the JuJu Royal Premium Marijuana collection. The intent is to make these strains available to dispensaries and caregivers on a worldwide basis where it is legal.

International Cannabrands Contact:

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR THEIR REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward Looking Statements

This news release contains forward-looking statements relating to expectations about the benefits of an agreement between the Company and Bang DigitalMedia Inc. for marketing and social media related services for its JuJu Royal brand. These forward looking statements involve risks and uncertainties. Events or circumstances may cause actual results to differ materially from those anticipated as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company or the parties to the agreement. These include legal and regulatory changes, the impact of general economic, industry and market conditions; expectations regarding market demand for particular products and the dependence on new product development; the impact of product competition. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Management of the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

To view the original release, please click here

Source: International Cannabrands Inc. (CSE:JUJU.A, OTC Bulletin Board:GEATF)

To follow International Cannabrands Inc. on your favorite social media platform or financial websites, please click on the icons below.

The post International Cannabrands Ltd Partners with Bang Holdings Corp to Launch New Digital Marketing Strategy for Julian Marley’s Brand appeared first on CannabisFN.

Gary Symons, Director of Communications, communications@delta9.ca, 250.300.9352Copyright CNW Group 2018

The post Delta 9 Signs Agreements to Acquire 180,000 Square Feet of Warehouse Space and 47 Acres of Land in Winnipeg for Expansion of its Production Facilities appeared first on CannabisFN.

The post RavenQuest Obtains OTCQB Listing Under Symbol “RVVQF” appeared first on CannabisFN.

Vancouver, B.C. (FSCwire) – Friday Night Inc. (the Company or Friday Night) (CSE: TGIF) (FWB: 1QF) (OTCQB: TGIFF), is pleased to announce its inclusion in the CSE25 Index which is comprised of the 25 largest companies in the Canadian Securities Exchange (“CSE”) Composite Index by market capitalization.

The CSE25 Index is a subset of the CSE Composite Index. This sub-index contains over 52.75% of the total weight of the Composite Index and typically includes stocks that attract considerable trading volume.

Brayden Sutton, CEO of Friday Night, remarked, “We are very proud to be recognized as one of the 25 largest companies on the CSE by market capitalization. The inclusion on the CSE25 Index not only distinguishes our Company as a highly liquid issuer but gives validation to our business strategy and recognizes our impressive growth over the last 9 months of trading.”

Richard Carleton, CSE CEO, observed that “As the exchange has grown rapidly in terms of trading volumes and market capitalization it is appropriate that we give market participants a benchmark that monitors the performance of our largest and most liquid issues. As the ‘exchange for entrepreneurs’ we are proud of their success in the Canadian capital markets.”

For more information on the CSE25 Index, please visit: http://thecse.com/en/trading/market-activity/cse-indices

About Friday Night Inc.

Friday Night Inc. is a Canadian public company, which owns and controls cannabis and hemp-based assets in Las Vegas Nevada as well as an international cannabis and mining security logistics consulting firm. The Company owns 91% of Alternative Medicine Association, LC (AMA), a licensed medical and adult-use cannabis cultivation and production facility that produces its own line of unique cannabis-based products and manufactures other third-party brands.  Infused MFG, also a 91% owned subsidiary, produces hemp-based, CBD products, thoughtfully crafted of high quality organic botanical ingredients.  The Company’s wholly-owned subsidiary, Spire Secure Logistics is a leading provider of customized security programs, compliance, information technology, buildout design, and due diligence services for the legal cannabis, mining and investment sectors. Friday Night Inc. is focused on strengthening and expanding its current operations.

For further information please contact:

Alexia Helgason, Corporate Communications

604-674-4756 (ext. 1)

Alexia@FridayNightInc.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.   Friday Night undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Source: Friday Night Inc (CSE:TGIF, OTCQB:TGIFF, FWB:1QF)

To follow Friday Night Inc on your favorite social media platform or financial websites, please click on the icons below.

The post Friday Night Inc. Named to the Canadian Securities Exchange’s CSE25 Index as One of the Largest Companies by Market Cap appeared first on CannabisFN.

Vancouver, British Columbia, March 20, 2018 (GLOBE NEWSWIRE) — Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) is pleased to announce that it has closed on the previously announced investment in BCWC, LLC (“BCWC”), formerly known as Bristol County Wellness Center, Inc. BCWC was recently awarded a special permit from the City of Attleboro and a provisional license from the Department of Public Health to build and operate a 24,700-sq ft. Registered Marijuana Dispensary (“RMD”) that will grow and sell medical marijuana.  This vertically integrated license allows BCWC to build out its facility and engage in cannabis cultivation, processing and retailing.  BCWC plans to add two additional retail outlets when suitable locations are identified and required approvals are obtained.

Mr. William Gildea, CEO of Future Farm, comments, “We are pleased to be working with the experienced team at BCWC and thrilled about the potential to operate in Massachusetts since it further positions our Company for revenue growth in 2018.” He continues, “This transaction allows us to operate in a state that has approved, but not yet implemented, the adult use of cannabis, which positions us as one of the first movers in the state.”  In Massachusetts, licensed RMDs and applicants with provisional licenses (such as BCWC) applying for an adult use license are eligible for prioritized application review by the state.

The timetable calls for construction to begin in the next thirty days, and revenue to begin in the fourth quarter of 2018. BCWC is provisionally licensed to cultivate cannabis with up to 300 lights, process and extract oil to make edibles, and sell through up to three medical dispensary locations. BCWC may also sell up to 30% of its cannabis to other dispensaries. ArcView Market Research and New Frontier Research each estimate the adult use recreational market in Massachusetts to have annual sales in excess of $1 billion by 2020.

Derek Ross, BCWC’s Manager, comments, “Unlike other states such as Colorado, Washington or California, where adult cannabis use is legal, Massachusetts is located within driving distance to many of the most densely populated states in the US. We anticipate that our facility, which will be conveniently located 1.5 miles from Exit 1 on I-95, will contribute to an increase in the Massachusetts cannabis tourism industry, providing state revenue, tax dollars, and job growth.”

Future Farm made its investment by loaning BCWC $5,003,100 under a Secured Convertible Promissory Note.  That Note will convert automatically into a 51% ownership interest in BCWC on the date on which BCWC receives its RMD Certificate from the Commonwealth of Massachusetts.  If the Note does not convert, it is due and payable in full on May 1, 2019.  In addition, Future Farm has entered into consulting contracts with each of the owners of BCWC for those individuals to advise Future Farm on the development of the BCWC facilities and business.  The aggregate consideration for the consulting services to be provided by all of the individuals is the issuance of 2,925,514 Common Shares of Future Farm.

For further information, contact William Gildea, Director, at (888) 387-3761.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman & CEO

About Future Farm

Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land.  The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability. The Company also utilizes a leading cannabis oil extraction technology, which enables the Company to process 20lbs/hour of cannabis plant to yield approximately 908 grams/hour of oil.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com, which caters to B2B customers, is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com, which caters to both large and small agriculture green houses and controlled cultivation centers.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. 

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

William Gildea, CEO & Chairman
888-387-3761
bill@futurefarmtech.com

The post Future Farm Acquires Controlling Interest in Massachusetts Licensed Cannabis Grow and Dispensary appeared first on CannabisFN.

KELOWNA, BC / ACCESSWIRE / March 20, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ”Company” or ”Lexaria”), a drug delivery platform innovator, is pleased to announce it has filed a new patent application with the United States Patent and Trademark Office (”USPTO”) for use of DehydraTECH^TM to improve the speed and quantity of absorption of active pharmaceutical ingredients (”API”) through the skin.

The patent application follows the recently announced successful laboratory evaluation of DehydraTECH^TM in the transdermal delivery of cannabidiol (”CBD”) that showed as much as a 225% increase in CBD permeability compared to control formulations tested with leading commercial penetration enhancers; and almost a 1,900% increase in CBD permeability compared to a control formulation that was devoid of both the DehydraTECH^TM technology or any commercial penetration enhancers. The original research protocols were overseen by Lexaria President John Docherty and represent a unique, new and improved method of transdermal delivery for cannabinoids and potentially many other active ingredients.

In the patent application, Lexaria has applied for patent protection for the delivery of all of the active ingredient classes already identified in its other issued and pending patent applications including cannabinoids, terpenes and terpenoids, NSAIDs, vitamins, nicotine and phosphodiesterase inhibitors, as well as a broad range of additional active ingredients commonly found in topical products today that may benefit from enhanced skin permeability performance in concert with the DehydraTECH^TM technology.

The Company believes that its DehydraTECH^TM technology could drive significant innovation and improvement for the delivery of active ingredients through topical products, transdermal patches, cosmetics and many other skin-oriented consumer product formats. Lexaria will initiate third-party licensing discussions for this new transdermal application of DehyrdaTECH^TM as soon as possible.

Lexaria’s patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used API substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria’s patented technology. Lexaria’s long term strategy is to partner with the world’s leading firms as they deliver best-of-class products to their existing large consumer groups.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH^TM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) and on Facebook http://tinyurl.com/y8vzcaam.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897

Or

NetworkNewsWire (NNW)
www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as ”anticipate,” ”if,” ”believe,” ”plan,” ”estimate,” ”expect,” ”intend,” ”may,” ”could,” ”should,” ”will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

The post Lexaria Files New Patent Application for Enhanced Transdermal Delivery System appeared first on CannabisFN.

The post RavenQuest Signs MOU With Fort McMurray #468 First Nation appeared first on CannabisFN.

CTI’s Extraction Facility Quickly Advancing Towards Full Commercialization

VANCOUVER, British Columbia, March 19, 2018 (GLOBE NEWSWIRE) — FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (OTCQB:FNNZF) announces that it has received its listing on the OTCQB under the symbol “FNNZF” and provides the following update on the interim medical cannabis extraction facility (“Extraction Facility”) of Cultivation Technologies Inc (“CTI”), FinCanna’s first investment in California.  As announced on January 15, 2018, CTI took over direct operations of its Extraction Facility operating at its site in Coachella, California and CTI has the rights to 100% of the production capacity.

CTI is quickly advancing towards commercialization and ramping revenue at the Extraction Facility from which FinCanna is entitled to receive 50% of the profits.

This Extraction Facility can currently process an estimated 6,000 pounds of biomass per month translating to approximately 3.7 million grams of raw oil per year. CTI has the ability to add an additional extraction machine and fractional distillation and winterization equipment.  This would result in additional capacity to process 3,000 pounds of biomass per month and the ability to service third-party vaporizer, winterization and distillation customers at a scale of approximately 100,000 grams of finished product weekly.

CTI’s Coachella Premium Brand

CTI’s own brand, Coachella Premium, recently introduced a line of medical concentrates which are now available for sale to all California licensed dispensaries. CTI is currently expanding its product line to include vaporizer cartridges, which will become available in the coming weeks. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

Manufacturing and Distribution Services

Since taking operational control at its Extraction Facility, and after obtaining state temporary licenses, CTI has acquired key accounts for contracted manufacturing and distribution. Private label services have commenced at the site, providing brands which otherwise had no legal avenue to participate in the licensed environment, a legal solution to maintain their presence in the market.

Implementation of Commercial Sales Team

To commercially advance these opportunities, CTI has hired an experienced sales team consisting of a director of sales, two full-time sales managers, and three independent sales contractors.  Chip Coble, the Company’s new director of sales, joined the CTI team in the beginning of March and brings with him over 25 years of channel sales and operations management, overseeing teams as big as 100 and managing multi-million-dollar budgets.  He will be overseeing the sales of CTI’s exclusive line of branded cannabis products: Coachella Premium^TM, as well as direct B2B sales under CTI’s manufacturing and distribution operations. CTI’s sales organization is strategically set up to serve designated zones throughout California to ensure statewide market penetration.

Industry Developments

The state of California is taking steps to curtail the operations of the black market.  Regulators have begun sending cease and desist letters to unlicensed operators, including advertising companies which have continued to support unlicensed operators.  In addition, an effort to support the businesses which have invested time and capital to reach legal status has begun with the introduction of amendments to Assembly Bill (3157).  The amendments propose to reduce the price disparity between legal cannabis business and black-market sources by suspending the state’s cultivation tax and reducing the state’s excise tax until 2021. These efforts highlight the state’s support for compliant business, strengthening the value proposition and opportunity in front of compliant operators such as CTI.

With the passing of Proposition 64 in November 2016 and legalization of adult use taking effect January 1, 2018, the state of California is now the world’s largest regulated cannabis market and estimated to be worth $6.45 billion by 2020. More information on the effects of the changing landscape in California can be found here.

About Cultivation Technologies
Cultivation Technologies, Inc. provides infrastructure, technology, and branding to the licensed medical cannabis industry. The first major project for the company is in Coachella, California, which will span 6-acres featuring cultivation centers, extraction and manufacturing facilities, a testing lab, a distribution hub, and a centralized processing center. For more information, visit www.CultivationTech.com.

About FinCanna Capital Corp.
FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues.  FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S. legal states, with a focus on California.  For additional information visit www.fincannacapital.com and FinCanna’s profile at www.sedar.com.

FinCanna Capital Corp.
Andriyko Herchak, CEO & Director

Investor Relations:
Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Forward-Looking Information

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about FinCanna’s ability to source suitable projects, the development and construction of the CTI’s facility at Coachella, and the size and success of operations at the Extraction Facility and FinCanna’s ability to generate revenues therefrom.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

The post FinCanna Provides an Update on CTI’s Medical Cannabis Extraction Facility in Coachella, California and Receives OTC Listing appeared first on CannabisFN.

VANCOUVER, British Columbia, March 19, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to announce it has signed a letter of intent (the “LOI“) with dicentra Inc. (“dicentra“) to establish a regulatory services partnership (the “Partnership“) under which dicentra will provide a suite of services to support Abattis’s current and future regulatory and compliance needs. Pursuant to the LOI, Abattis and dicentra have agreed to negotiate in good faith the terms of a definitive agreement respecting the Partnership, which agreement will include representations, warranties and covenants typical for an arrangement of similar nature to the Partnership and will supersede the LOI.

With more than 1,000 clients served internationally, over 15,000 projects successfully completed and offices in Canada and the United States, dicentra is a leading consulting firm with 16 years of experience providing regulatory and compliance services.

“Bringing dicentra’s experience and expertise to Abattis will help us to secure world-class regulatory and compliance services for Abattis and our clients and partners”, stated Rob Abenante, President and CEO of Abattis.

“The Partnership will support our commitment to develop and manufacture food and beverages, cosmetics, pet products and over-the-counter health supplements containing cannabinoids that are compliant with current and future regulations in Canada and the United States”, added Mr. Abenante.

“After more than 16 years of experience working with Health Canada’s regulatory framework and the US Food and Drug Administration (FDA), we feel confident dicentra has the necessary experience and expertise needed to support Abattis’s expansion plans”, stated Dr. Karol Wojewnik, Vice President of Business Development (Life Sciences) at dicentra.

“The Partnership, paired with our state-of-the-art analytical services, will represent an additional step towards vertically integrating a full suite of world-class services for our clients”, stated Dr. David Galvez, Senior Science Advisor at Abattis.

About dicentra

dicentra is a professional consulting firm that specializes in addressing all matters related to safety, quality and compliance for all product categories in the life sciences and food industries.

Since inception in 2002, dicentra has completed over 15,000 projects and serviced nearly 1000 companies internationally.

About Abattis

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

“Rob Abenante”

Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: the proposed Partnership; that dicentra’s experience and expertise will help Abattis secure world-class regulatory and compliance services for Abattis and its clients and partners; that the Partnership will support Abattis’s commitment to develop and manufacture food and beverages, cosmetics, pet products and over-the-counter health supplements containing cannabinoids that are compliant with current and future regulations in Canada and the United States; and that the Partnership, paired with Abattis’s state-of-the-art analytical services, will represent an additional step towards vertically integrating a full suite of world-class services for Abattis’s clients. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that a definitive agreement respecting the Partnership will not be entered into or that the Partnership will not be formed; that dicentra’s experience and expertise will not help Abattis secure world-class regulatory and compliance services for Abattis and its clients and partners; that the Partnership will not support Abattis’s commitment to develop and manufacture food and beverages, cosmetics, pet products and over-the-counter health supplements containing cannabinoids that are compliant with current and future regulations in Canada and the United States; that the Partnership, paired with Abattis’s state-of-the-art analytical services, will not represent an additional step towards vertically integrating a full suite of world-class services for Abattis’s clients; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

The post Abattis Strengthens Regulatory Services Offerings through Partnership with dicentra appeared first on CannabisFN.

VANCOUVER and NAPANEE, ON, March 19, 2018 /CNW/ – Choom™ (CSE: CHOO; OTCQB: CHOOF) (the “Company” or “Choom”) and ABcann Global Corporation (“ABcann”) (TSXV: ABCN, OTCQB: ABCCF) are pleased to announce that the Company has completed a financing of subscription receipts (each, a “Subscription Receipt”) for gross proceeds of $7.0 million including a $4.0 million lead order from ABcann.

Strategic Subscription Receipt Financing – $7.0 million

Further to Choom’s news release of March 19, 2018, the Company announces that it has completed a strategic private placement of Subscription Receipts concurrent with the execution of a definitive agreement relating to the acquisition of International Tungsten Inc. (“ITI”). In total 11,666,991 Subscription Receipts were issued for gross proceeds of $7.0 million(the “Offering”), including a strategic $4.0 million lead order from ABcann.

“ABcann remains committed to becoming a global leader in the cannabis sector. With our strategic investment in Choom, we are signaling a strong move into the recreational market with one of the premium recreation brands in Canada,” stated Barry Fishman, CEO of ABcann. “With our strong cash position of approximately $135,000,000, ABcann intends to pursue other accretive opportunities to diversify our industry presence. We look forward to working with and assisting the Choom team with the supply of our premium grown products.”

Supply Agreement

Additionally, Choom™ has entered into a binding agreement (the “Supply Agreement”) with ABcann whereby ABcann, one of Canada’s premier growers, will supply Choom™ with premium cannabis products, subject to regulatory approval.

“The Supply Agreement will demonstrate our commitment to becoming one of Canada’s leading retailers in the cannabis space. Working with ABcann will provide us with a premium line of products, with a strong focus on quality, in the roll-out of our retail store strategy, upon receipt of applicable regulatory approvals,” stated Chris Bogart, President and CEO of Choom™. “As we expand our efforts to strengthen our retail platform and brand position, a partnership with one of the market leaders in quality and production will be of great value to our organization. The investment and supply agreement with ABcann is a strong endorsement of our strategy and a pivotal step in developing Choom™ as the premium brand in Canada’s burgeoning recreational cannabis market.”

Subscription Receipt – Unit Offering

The proceeds from the Offering are being held in escrow until the completion of the acquisition of ITI (the “Transaction”). Upon closing of the Transaction and satisfaction of the other escrow release conditions, each Subscription Receipt will be automatically converted, for no additional consideration and without any further action by the holder of such Subscription Receipt, into one unit of the Company (each a “Unit”). If the escrow release conditions are not satisfied by June 11, 2018, the Subscription Receipts will be cancelled and the escrowed proceeds from the Offering will be returned to the holders of the Subscription Receipts pro rata. For further details with respect to the Transaction, please see Choom’s news release dated March 19, 2018, a copy of which is available under Choom’s profile on SEDAR at www.sedar.com.

Each Unit will consist of one common share of the Company (each, a “Common Share”) and one common share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one common share of the Company for a period of 18 months from the date of issuance at a price of $0.90 per Common Share. In the event that, following the conversion of the Subscription Receipts into Units, the 10-day volume weighted average trading price of the Common Shares on the Canadian Securities Exchange is above $1.35, the expiry date of the Warrants will be accelerated to a date that is 30 days after the Company disseminates a news release announcing the accelerated expiry date.

The Subscription Receipts, and any Common Shares and Warrants issued upon conversion thereof, will be subject to a hold period expiring four months and one day after the closing of the Offering. The proceeds from the Offering will be used to cover costs of the Transaction, production facility improvements and for general working capital purposes.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there by any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

SAY HELLO TO CHOOM^TM

Choom™ was created for and inspired by the Choom Gang; a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom“. Now, after four decades, Choom™ is bringing the spirit of Hawaii to Canada. We’re planting our flag in the rapidly growing legal cannabis industry in Canada with our own brand of high-grade handcrafted herb. Choom™ will provide an amazing experience for customers, and bring style, sophistication and fun to the cannabis market through our Choom™ stores.

“Chris Bogart”
President & CEO

About ABcann:

ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products. ABcann is expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.

“Barry Fishman”
CEO and Director 

Cautionary Statement:

NEITHER OF THE TSX VENTURE EXCHANGE, THE CANADIAN SECURITIES EXCHANGE NOR THEIR REGULATIONS SERVICES PROVIDERS, HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking information                 
Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Transaction and Choom’s or ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to the terms of the Transaction and the Offering; the expected benefits of, and impact on, the cannabis industry; and other statements regarding the business of Choom or ABcann. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including the risk that the CSE may not approve the Transaction, the Offering or the Supply Agreement; that the Transaction, the Offering or the Supply Agreement may not be completed for any other reason; or that factors may occur which impede or prevent Choom’s future business and development plans. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits Choom or ABcann will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and Choom and ABcann disclaim any intent or obligation to update publicly any forward looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE Choom Holdings Inc.

The post Choom™ and ABcann Announce Strategic Investment and Supply Agreement appeared first on CannabisFN.

VANCOUVER, March 19, 2018 /CNW/ – Choom™ (CSE: CHOO; OTCQB: CHOOF) (the “Company” or “Choom”) is pleased to announce that the Company has entered into a definitive amalgamation agreement, effective March 16, 2018 (the “Definitive Agreement”), among itself, its wholly-owned subsidiary, Arbutus Brands Inc. (“Arbutus Brands”), and International Tungsten Inc. (“ITI”). Pursuant to the Definitive Agreement: (i) Arbutus Brands will amalgamate with ITI, with the amalgamated company remaining a wholly-owned subsidiary of the Company operating under the name of Arbutus Brands, and (ii) all of the issued and outstanding securities of ITI will be exchanged for securities of Choom (the “Transaction”). ITI has entered into an agreement to acquire all of the issued and outstanding securities of Specialty Medijuana Products Inc. (“SMP”), an applicant under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), that has submitted its Affirmation of Readiness (“AOR”) evidence package to Health Canada and expects to receive a cultivation license from Health Canada within the next several weeks.

Transaction Highlights

The expected benefits of the Transaction for Choom™ include that it will:

• enable Choom™ to acquire a company in British Columbia that has submitted its AOR evidence package to Health Canada and expects to receive its cultivation license in the next few weeks;
• create significant synergies in operational infrastructure and expertise across multiple disciplines to drive strong growth potential;
• significantly improve and advance operational scale and production capacity; and
• strengthen and accelerate Choom’s strategic direction as a fully-integrated cannabis company, representing a premiere lifestyle brand in Canada.

Specialty Medijuana Products Inc.

SMP, based in Canada’s beautiful Sooke, B.C., is committed to becoming a Licensed Producer of cannabis under the ACMPR. SMP was founded by a seasoned business team with extensive experience in growing cannabis, the operation of pharmacies, medical clinics, land development and construction. The SMP team, in conjunction with Choom’s™ management team, plan to build upon their collective past business successes and leverage their expertise to create Canada’s premiere lifestyle brand in adult-use cannabis.

Facility Overview

SMP’s marijuana production growth strategy is expected to be executed in three phases:

• Phase I – First Facilities: AOR evidence package submitted to Health Canada:  Buildings are at operational readiness with state-of-the-art-facilities, consistent with ACMPR standards, and SMP expects to receive its cultivation license from Health Canada within the next several weeks. A sales license is expected to be granted by Health Canada in the third quarter of 2018.
• Phase II – Second Facility: Expand existing production by constructing an approximately 19,600 sq. ft. facility that will bring total production capacity to over 29,000 sq. ft. in the combined facility footprint.
• Phase III – New Facility:  Expand existing production by constructing two additional buildings that will increase the total building gross square footage to just over 700,000 sq. ft. This new facility, a hybrid model of indoor and greenhouse production, is expected to bring Choom’s total production capacity to over 750,000 sq. ft. The Municipality of Sooke has already approved cannabis production zoning for the site. The building expansion fits within the zoning regulations and final planning for this expansion is currently underway.

The SMP Team

SMP’s team has the experience to ensure that they successfully navigate the ACMPR licensing process and deliver on their vision. The SMP team includes:

Michael Forbes

Named one of 2017’s Top Entrepreneurs by Quantum Shift, Michael has a long history of creating and operating successful companies in the pharmaceutical and health care industries. Over the course of 14 years in business, he has created and operated a chain of nine pharmacies and eight medical clinics, including three methadone clinics, employing over 160 people.

This expertise led to him being nominated to help create the procedures for the College of Pharmacists of British Columbiain 2010. His expertise in creating standard operating procedures in the pharmaceutical space is vital in ensuring proper drug dispensing to the public. This experience is crucial in creating trust with the consumer and the industry at large. He holds an Honorary Degree in Business from the Ivey School of Business and a Bachelor of Science, Pharmacy.  Mr. Forbes will be joining the Choom™ Board of Directors upon the completion of the Transaction.

Ian Laing

Ian has over 20 years of experience in real estate, development and construction in a range of areas, including apartment buildings, custom home construction, land development, rezoning, condominiums, commercial and industrial buildings.

Since 1998, Ian has consistently proven his ability to build and grow multi-million dollar projects from the ground up. He has a background in Urban Land Economics from the University of British Columbia and a commitment to building with integrity. Ian is currently running four companies, and has experience in the recreational space with Salt Spring Island Brewery. This experience is expected to benefit the development of SMP’s business practices and the anticipated build out and scaling of facilities. SMP will rely on this expertise as it grows its facilities and expands operations.

Neil Michael MacLean

Neil MacLean has over 20 years of experience with the Department of National Defence (“DND”), primarily dealing with electronics, and previously was an environmental officer for HMCS Huron. His safety and WHMIS training, combined with his understanding of security procedures, are expected to assist SMP with compliance with the highest level of government regulations. He has effectively managed the integration of new equipment and systems, and has extensive personnel training experience, which, together with his training in environmental issues, electronics and operations of complex systems, will support the operational side of SMP.

Transaction Summary

In accordance with the terms of the Definitive Agreement, ITI will amalgamate with Arbutus Brands following which the resulting amalgamated entity will continue as a wholly-owned subsidiary of the Company. In consideration for the completion of the Transaction, the holders of ITI common shares will be issued one common share of the Company (each, a “Common Share”) in exchange for every share of ITI held, up to a combined maximum of 92,000,000 Common Shares. Existing convertible securities of ITI will be exchanged for convertible securities of the Company on substantially the same terms, and applying the same exchange ratio. In connection with the closing of the Transaction, Choom will pay finder’s fees of 4,000,000 Common Shares to eligible parties.

In connection with the Transaction, Choom has completed an offering of subscription receipts, at a price of $0.60 per subscription receipt, for aggregate gross proceeds of $7.0 million (the “Offering”). The proceeds of the Offering are being held in escrow until the completion of the Transaction, after which each subscription receipt will be automatically converted, for no additional consideration and without any further action by the holder, into one unit of Choom, with each unit being comprised of one Common Share and one common share purchase warrant, each of which will be exercisable into one Common Share at a price of $0.90 per Common Share for 18 months following the date of issuance (subject to acceleration in certain circumstances in accordance with the terms thereof).

The closing of the Transaction remains subject to a number of conditions, including the completion of satisfactory due diligence, receipt of any required shareholder, regulatory and third-party consents, the acquisition by ITI of SMP, and the satisfaction of other customary closing conditions. Additional information regarding the Transaction will be made available under the Company’s profile on SEDAR (www.sedar.com) as such information becomes available.

There can be no assurance that the Transaction will be completed as proposed, or at all.

The Canadian Securities Exchange has not in any way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release.

None of the securities issued in connection with the Transaction or the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there by any sale of the securities, in any state where such offer, solicitation, or sale would be unlawful.

SAY HELLO TO CHOOM^TM
Choom™ was created for and inspired by the Choom Gang; a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom“. Now, after four decades, Choom™ is bringing the spirit of Hawaii to Canada. We’re planting our flag in the rapidly growing legal cannabis industry in Canada with our own brand of high-grade handcrafted herb. Choom™ will provide an amazing experience for customers, and bring style, sophistication and fun to the cannabis market with through our Choom™ stores.

ON BEHALF OF THE BOARD OF DIRECTORS OF CHOOM:

Chris Bogart
President & CEO

Cautionary Statement:

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking information                 
Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Transaction and Choom’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future.  Forward looking statements in this news release include statements relating to the Transaction; the Offering; and the business of the Choom following the closing of the Transaction. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including the risk that the Canadian Securities Exchange may not approve the Transaction; that the Transaction may not be completed for any other reason; or that factors may occur which impede or prevent attainment of Chooms proposed future business plans. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits Choom will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and Choom disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE Choom Holdings Inc.

The post Choom™ Signs Definitive Amalgamation Agreement to Acquire Late Stage ACMPR Applicant with Affirmation of Readiness Evidence Package Submitted to Health Canada appeared first on CannabisFN.

VANCOUVER, British Columbia, March 19, 2018 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) (Frankfurt:1IT) is proud to announce that it has signed a Memorandum of Understanding with Fort McMurray #468 First Nation (“FM 468”) to collaborate in the development, operation and financing of a purpose-built facility for the production of cannabis on lands controlled by FM 468.

RavenQuest has developed an indigenous-centered, end-to-end solution for cannabis production and sale on sovereign land.  RavenQuest will provide its expertise to deliver the technical know-how, staff resources, and financing opportunities as they relate to the development of the Production Facility, initially sized at 24,000 square feet.  In consideration, RavenQuest will receive a thirty percent (30%) ownership interest in such a facility.

The parties intend that the Production Facility will rapidly expand from its initial development to a maximum of 250,000 square feet.  Under such an arrangement RavenQuest will be granted the rights to a perpetual stream of a portion of cannabis produced at the Production Facility.  Any joint venture arrangement will include provisions for the continued development and expansion of the production facility.

“This MOU represents a key milestone for our organization,” said George Robinson, CEO of RavenQuest.  “We intend to emerge as the trusted provider of choice for Indigenous Peoples’ Cannabis industry partnerships across Canada.  Our work in this area reflects a high level of understanding of the concerns and issues facing Indigenous communities across Canada.  With the right partners, we see cannabis as a tremendous opportunity for economic diversification, self-reliance, employment and harm reduction within Indigenous communities.  This agreement is designed to deliver on all of these fronts, providing for a mutually beneficial arrangement for FM 468 and RavenQuest moving forward.”

“By participating in the cannabis sector, it will allow Fort McMurray #468 First Nation to take one step closer to being a self-sufficient Nation for the next seven generations and providing world-class services to the Citizens,” said Chief Ron Kreutzer.

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications – 604-484-1230

Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including statements with respect to the development of a licensed cannabis production facility and anticipated production from such a facility. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

The post RavenQuest Signs MOU With Fort McMurray #468 First Nation appeared first on CannabisFN.

GATINEAU, Quebec, March 16, 2018 (GLOBE NEWSWIRE) — The Hydropothecary Corporation (TSXV:THCX) (“Hydropothecary” or the “Company”) is pleased to announce its agreement with Segra International Corp. (“Segra”) to incorporate plant tissue culture propagation into the cannabis plant production process. Segra’s expertise and unique tissue culture technique will allow Hydropothecary to increase its yield of healthy, top-quality plants to serve the growing medical and recreational cannabis markets.

“Working with Segra will allow us to meet one of the biggest challenges as we meet the demand for cannabis products across Canada and beyond, balancing quality and quantity in our cannabis production,” said Sebastien St-Louis, Hydropothecary’s CEO and co-founder. “Thanks to Segra’s plant tissue culture technique, we will scale up our production process while maintaining the industry-leading quality standards that have made us so successful.”

Segra specializes in industrial-scale cannabis micropropagation, also known as plant tissue culture. This process replaces traditional cloning from mother plants with rapid, sterile production of robust and healthy plantlets. It generates exact copies of the original plant without the risk of pathogens, fungi, and other issues that can plague other industrial-scale production processes.

The agreement with Segra will play a crucial role in scaling up Hydropothecary’s cannabis plant production to meet market demand in the recreational cannabis market across Canada, expected to begin this summer. The Company is on track to complete previously announced facility expansions increasing annual production capacity to 108,000 kg of dried cannabis, making Hydropothecary one of Canada’s largest producers.

Working with Hydropothecary’s Master Grower, Agnes Kwasniewska and her team, Segra will set up a laboratory at Hydropothecary’s facility in Gatineau, Quebec to begin the initialization phase of the plant tissue culture process. Once the system is established, production will rapidly scale into millions of plantlets per year.

“We are honoured to be working with Hydropothecary,” said Todd McMurray, President and CEO of Segra. “Our companies both have well-earned reputations for innovation and quality in our respective fields. This agreement is the perfect combination of skills and expertise to produce great-quality cannabis products for customers.”

About Segra International

Segra is a plant biotechnology company that specializes in industrial-scale cannabis plant micropropagation. The company is developing industrial-scale cannabis micropropagation laboratories to produce healthy, robust plantlets for licensed cannabis producers globally. Segra has assembled a world-class team of specialists in the areas of plant tissue culture, agronomy, molecular genetics, regulatory compliance, and corporate finance. The Segra team includes Dr. Sma Zobayed, Segra’s Director of Micropropagation. Dr. Zobayed is a world-renowned micropropagation specialist who has successfully micropropagated over 500 species of plants including cannabis. Dr. Zobayed has successfully developed a protocol for true-to-type cannabis micropropagation (including 4 – 7 x multiplication of plant stock over a 30-day period).  Segra will help its clients improve product quality, rapidly expand operations, decrease liabilities associated with pest and disease, and increase profits.

About Hydropothecary Corporation

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations. Hydropothecary creates award-winning innovative, easy to use and easy to understand products. Hydropothecary is rapidly increasing its production capacity in the lead-up to recreational adult-use cannabis. Expansion plans will result in a total of 1.3 million sq. ft. of production space, producing 108,000 kg of dried cannabis per year, making Hydropothecary one of the largest producers in the country. With industry-leading cash cost per gram of $0.89, Hydropothecary is the lowest cost producer in the country. The first licensed producer in Quebec, Hydropothecary is headquartered in the province.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Media Contact Information

Shawn Lyons
Manager, Media Relations and Strategic Communications
819-576-3637
shawn.lyons@thehydropothecary.com

Investor Relations Contact Information

Jennifer Smith
Manager of Financial Reporting and Investor Relations
1-866-438-THCX (8429)
invest@THCX.com
www.THCX.com

Director

Adam Miron
819-639-5498

The post Hydropothecary partners with Segra to scale-up production in preparation for cannabis legalization appeared first on CannabisFN.

WINNIPEG , March 15, 2018 /CNW/ – DELTA 9 CANNABIS INC. (NINE.V) (“Delta 9” or the “Company”) has signed a Memorandum of Understanding to purchase up to 5,000 kilograms of cannabis from Alberta -based Sundial Growers Inc. (“Sundial”).

The purchase is designed to increase Delta 9’s ability to meet the anticipated market demand following the full legalization of adult-use cannabis in Canada . The agreement commits Sundial to supply up to 5,000 kilograms of both dried cannabis and/or cannabis derivatives “to meet or exceed” Delta 9’s market demand in the period post-legalization. Delta 9 CEO John Arbuthnot says the agreement was reached as part of the company’s commitment to supply the Manitoba market. Delta 9 and partner Canopy Growth Corporation (Canopy Growth) (WEED.TO) were selected in February by the Manitoba government as one of four successful bidders to a license to retail cannabis in the province.

Delta 9 and Canopy Growth have committed a significant supply of cannabis product for the provincial market. Delta 9 is increasing its annual production in Manitoba to 17.5 million grams per year by the end of 2019.

“We’ve committed to producing a baseline amount of product for the Manitoba market, and we are confident we can achieve those numbers,” said Arbuthnot. “However, we would like to exceed those projections in order to not only meet demand in Manitoba , but also meet or exceed our commitments to national sales under our CraftGrow agreement with Canopy Growth.”

Delta 9 and Canopy Growth announced in December that Delta 9 had joined Canopy Growth’s CraftGrow program. The agreement provides Delta 9 with a national sales channel to supplement to the Company’s strong presence in Manitoba , says Arbuthnot. “No one can really predict what will happen in the cannabis market in the first year after legalization, but early indicators are that demand will increase dramatically, and we intend to be ready for that demand,” he said.

The agreement is also beneficial for Sundial, which currently has a cultivation license but has not yet secured a license to sell from Health Canada. Sales can only take place through an already licensed producer such as Delta 9, which has the testing and quality assurance protocols in place to ensure compliance with Health Canada regulations.

“Sundial is committed to providing Canadians with quality products, and we are excited to work with Delta 9 to bring our products to market as legalization occurs next summer, said Sundial Chief Commercial Officer Andrew Stordeur . “We believe there are long term benefits to working together for both companies.”

The current agreement is a non-binding Memorandum of Understanding designed to set out the basic working relationship between the two companies. The parties intend to formalize the Supply Agreement in the near future. 

About Delta 9 Cannabis Inc.
Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada . Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE”.

About Sundial Growers Inc.
Sundial Growers Inc. (“Sundial”) is a privately held, Alberta -based Health Canada ACMPR-approved licensed producer of medical cannabis. Sundial combines tried and true heartland farming practices with innovative horticultural techniques to grow a select range of cannabis strains.  Our focus is on producing consistent cannabis that our customers can trust.

The post Delta 9 Signs Supply Agreement with Sundial Growers for 5,000 Kilograms of Cannabis appeared first on CannabisFN.

TORONTO, March 14, 2018 (GLOBE NEWSWIRE) — The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) today announced that it has filed an amended and restated preliminary long form prospectus (the “Prospectus”) with the securities regulatory authorities in each of the provinces of Canada in respect of its previously announced initial public offering of units of the Company (the “Units”).  The Prospectus contemplates a minimum offering of $75,000,000 and a maximum offering of $100,000,000 through the issuance of a minimum of 20,547,945 Units and a maximum of 27,397,260 Units (the “Offering”) at a price of $3.65 per Unit.

Each Unit consists of one common share of the Company (a “Unit Share”) and one-half of one common share purchase warrant of the Company (each whole warrant being a “Warrant”). Each Warrant is exercisable into one common share of the Company (a “Warrant Share”) at the price of $7.00 per Warrant Share, subject to adjustment, on or prior to 4:00 p.m. (Eastern Time) on the date that is the earlier of (i) 24 months after the Closing Date and (ii) the date specified in any Warrant Acceleration Notice (as hereinafter defined). If, at any time, the volume-weighted average trading price of the common shares of the Company is equal to or greater than $9.00 for any 10 consecutive trading day period, the Company may provide written notice to Computershare Trust Company of Canada as warrant indenture trustee and the registered holders of Warrants (a “Warrant Acceleration Notice”) that the expiry time of the Warrants shall be accelerated to the date which is 30 days after the date of such Warrant Acceleration Notice, subject to TSX approval.

The Offering is being led by Canaccord Genuity Corp. as sole bookrunner and co-led with PI Financial Corp. (collectively, the “Co-Lead Agents”), together with Industrial Alliance Securities Inc., INFOR Financial Inc., Echelon Wealth Partners Inc. and Mackie Research Capital Corporation as agents (collectively, the “Agents”).

The amended and restated preliminary prospectus contains important information relating to TGOD and the Units and is still subject to completion or amendment. Copies of the amended and restated preliminary prospectus are available from the Agents. There will not be any sale or any acceptance of an offer to buy the Units until a receipt for the (final) long form prospectus has been issued.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Units have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws. Accordingly, the Units may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of TGOD in any jurisdiction in which such offer, solicitation or sale would be unlawful.

On Behalf of the Board of Directors,

The Green Organic Dutchman Holdings Ltd.
Robert Anderson
Chief Executive Officer and Co-Chairman

ABOUT THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD.

The Company is licensed under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) to cultivate medical cannabis. The Company carries out its principal activities producing cannabis from its facilities in Ancaster, Ont., pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.

The Company grows high quality, organic medical cannabis with sustainable, all-natural principles. The Company’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product.

The Company has a funded capacity of 116,000 kg and is situated on approximately 175 acres of land between two of the most populated areas of Canada; Ontario & Quebec. The Company has negotiated favourable power rates and is building a combined 970,000 sq. ft. facility capable of producing 116,000 kg of premium, high- quality, organic cannabis. To date, the Company has raised approximately $160 million dollars and has over 4,000 shareholders.

CONTACT INFORMATION

Investor Relations
Email: invest@tgod.ca
Phone: 1 (416) 900-7621

www.tgod.ca

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”), including, but not limited to, statements with respect to the completion of TGOD’s initial public offering, completion of the Ancaster and Valleyfield facilities and the performance of TGOD. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

The post The Green Organic Dutchman Files Amended and Restated Preliminary Prospectus for Initial Public Offering of Units appeared first on CannabisFN.

The post RavenQuest Announces Dr. Simerjeet Kaur Will Lead Scientific Research & Development appeared first on CannabisFN.

The post Abattis Signs LOI with Canadian Artesian Ice, Bottlers of Clearly Canadian Products, to Manufacture CBD-infused Mineral Water appeared first on CannabisFN.

The post RISE Life Science Corp. Changes Its Stock Symbol to RLSC appeared first on CannabisFN.

VANCOUVER, British Columbia, March 13, 2018 /PRNewswire/ —

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE:FFT) (FFT.CN) (FFRMF) is pleased to announce that it has closed on a second investment of $4,000,000 USD from Yorkville Advisors Global, LP (“Yorkville”). Proceeds from the private placement will be used in part to acquire the previously announced, provisionally licensed Registered Marijuana Dispensary (“RMD”) in Attleboro, MA.

In January 2018, Future Farm signed a Letter of Intent to acquire an interest in Bristol County Wellness Center, Inc. (“BCWC”). BCWC was recently awarded a special permit from the City of Attleboro and a provisional license from the Department of Public Health to build and operate a 24,700-sq ft. RMD that will grow and sell medical marijuana, plus two additional dispensaries upon approval. This vertically integrated license allows BCWC to build out its facility and engage in cannabis cultivation, processing and retailing.

William Gildea, CEO of Future Farm comments, “We have been diligently working with the experienced team at BCWC to move this transaction to a quick close and are thrilled about the potential to participate in the operations of a Massachusetts RMD as it further positions our Company for revenue growth in 2018.”

The timetable calls for construction to begin right after closing, which is imminent, and revenue to begin in the fourth quarter of 2018. BCWC is provisionally licensed to cultivate cannabis with up to 300 lights, process and extract oil to make edibles, and sell through a medical dispensary. BCWC may also sell up to 30% of its cannabis to other dispensaries. ArcView Market Research & New Frontier Research estimates the legal cannabis market in Massachusetts to reach $1.07 Billion by 2020.

The Company is also pleased to provide an update with respect to the exercise of warrants. As of March 7, 2018, Future Farm’s $0.35 and $0.37 warrants have both expired. Since December 2017, the voluntary exercise of these warrants brought the Company a total of almost $2,000,000.

“These fundraising activities enable us to execute on some exciting projects we have lined up as well as expand on our existing portfolio,” explains Mr. Gildea.

The Company is also pleased to announce the appointment of a new auditor. Davidson & Company LLP, Chartered Professional Accountants (the “Former Auditor”) has been terminated and Dale Matheson Carr-Hilton Labonte LLP (“DMCL”
or the “Successor Auditor”) has been appointed as the new auditor, effective immediately. Reporting notices prepared in accordance with National Instrument 51-102 by the Former Auditor, the Successor Auditor and the Company have been filed on SEDAR.

DMCL is an independent Vancouver-based accounting firm with 20 partners and over 150 professional and support personnel. They are recognized for their expertise in audit and assurance, accounting, taxation and business advisory for public and private companies, not-for-profits and owner-managed businesses.

Under the terms of the Yorkville financing, the Company has agreed to enter into a Secured Convertible Debenture in the Principal Amount of $4,000,000 USD, bearing annual interest at 8% and repayable within 18-months, or convertible into Common Shares of the Company at a price of C$0.58 per share. In connection with the Debenture, the Company has also granted a Warrant Certificate to purchase 7,421,150 Common Shares at an average price of C$0.70 per share. The Warrant Certificate expires on March 7, 2021.

As further part of this financing, the Company will pay a 10% broker fee to Moody Capital Solutions Inc.

On behalf of the Board,
Future Farm Technologies Inc.
William Gildea, Chairman & CEO

About Future Farm

Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land. The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability. The Company also utilizes a leading cannabis oil extraction technology, which enables the Company to process 20lbs/hour of cannabis plant to yield approximately 908 grams/hour of oil.

The post Future Farm Closes on $4 Million USD Financing in Anticipation of Closing on Massachusetts Dispensary and Announces Appointment of New Auditor appeared first on CannabisFN.

Edmonton, Alberta and Vancouver, British Columbia–(Newsfile Corp. – March 13, 2018) – Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (FSE: 21P) (“Aurora“) and PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (“PreveCeutical“)  today announced the grant of three permits by the Australian Government, Department of Health, for the importation of cannabis into Australia for research purposes (the “Permits“). The Permits were granted to the Pharmacy Australia Centre of Excellence (“PACE“) at the University of Queensland (“UQ“) and allow PACE to import shipments of cannabis plant material for research purposes. Aurora, in turn, has received the required Canadian permits to export the cannabis to PACE.

The cannabis will be shipped from Canada by Aurora and used for PreveCeutical’s soluble gel (“Sol-gel“) drug delivery research program (the “Program“), which is being conducted by PreveCeutical’s research partner UniQuest Pty Inc. and led by PreveCeutical’s Chief Research Officer, Dr. Harendra Parekh. The Program aims to develop a system that will increase the bioavailability of drugs by using a nose-to-brain delivery system.

PreveCeutical intends to apply Sol-gel technology to cannabinoids to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders (see news release dated April 24, 2017). The Permits will enable PreveCeutical to test an array of cannabis strains for the development and commercialisation of cannabinoid-based Sol-gels. The advantages of Sol-gels over conventional liquid nasal sprays relate to longer therapeutic effects, reduced dosage requirements, and reduced irritation and other negative side effects.

In consideration of the shipment, Aurora has received certain rights, including the option to either license, on a non-exclusive basis, the technology for Canada and Australia, or to opt for a royalty arrangement on product sales, as well as to purchase shares in PreveCeutical.

“We see an important market for cannabis-based products that are more narrowly targeted at specific therapeutic areas but that are higher value add and being involved with initiatives such as PreveCeutical’s is part of our strategy to gain access to these types of products,” said Terry Booth, CEO of Aurora.

PreveCeutical’s CEO and Chairman, Mr. Stephen Van Deventer added, “We are extremely excited to receive the Permits, allowing us to further our Sol-gel research program with the high quality cannabis products provided by Aurora. The goal of the Program is to cultivate a range of therapies that will benefit people with ailments such as epilepsy, pain and inflammation, safely and economically.”

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as “Aurora Mountain”, and a second 40,000 square foot high-technology production facility known as “Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island. In January 2018, Aurora’s 800,000 square foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce over 100,000 kg per annum of cannabis. Aurora is completing a fourth facility in Lachute, Quebec utilizing its wholly owned subsidiary Aurora Larssen Projects Ltd.

Aurora also owns Berlin-based Pedanios, the leading wholesale importer, exporter, and distributor of medical cannabis in the European Union. The Company owns 51% of Aurora Nordic, which will be constructing a 1,000,000 square foot hybrid greenhouse in Odense, Denmark. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens.

The post Aurora Cannabis Exports Dried Cannabis Flower and Oils to Australia for Novel Nose-to-Brain Drug Delivery Research by PreveCeutical appeared first on CannabisFN.

Dr. Wolfgang Renz Appointed Pivot’s Chief Medical Officer

ancouver, British Columbia–(Newsfile Corp. – March 12, 2018) – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) (“Pivot” or the “Company”), is pleased to announce that the Company has retained Cannabis Compliance Inc. (“CCI”) to submit an application to Health Canada for a Dealer’s License (“Dealer’s License” or “DL”) under the Controlled Drugs and Substances Act (“CDSA”) and the Narcotic Control Regulations enacted thereunder on behalf of Agro-Biotech Inc. (“Agro-Biotech”). As previously announced on February 22, 2018, Pivot has entered into a letter of intent for the proposed acquisition of Agro-Biotech (the “Proposed Acquisition”). For further details on the Proposed Acquisition, please refer to the Company’s news release.

Agro-Biotech operates a fully licensed, purpose-built, indoor hydroponic cannabis production facility located in Saint-Eustache, Québec, 40 kilometres north of Montréal. Phase I is now complete and Phase II and Phase III are expected to be completed by the end of September 2018, resulting in a total grow area of 75,000 square feet, capable of producing a cumulative 10,000 kg per year. Agro-Biotech received its Producer’s License from Health Canada’s Office of Medical Cannabis on January 12, 2018. Upon the anticipated issuance of a Sales License from Health Canada, initial revenue is expected in Q3 2018.

Upon completion of the Proposed Acquisition, the Dealer’s License will enable Pivot, through Agro-Biotech, to conduct research and development (“R&D”) and store cannabis derivatives that are not currently covered under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). A Dealer’s License and export permit would position the Company to export cannabis oils and concentrates to available international markets, as well as to process natural health products. In addition, a DL will also allow the Company to prepare authorized manipulations, formulations, dosage forms, strengths or package sizes of cannabis expanding possible research and product innovation opportunities.

The facility design includes extraction and purification areas expected to be fully operational following the successful closing of the Proposed Acquisition and receipt by Agro-Biotech of a Dealer’s License from Health Canada. Agro-Biotech is one of only six Licensed Producers in Québec, Canada’s second largest province with a population of over 8.4 million people. Owners of 75 high quality cannabis strains, including high expressors of CBD, Agro-Biotech’s genetics will enable it to bring unique, differentiated cannabis products to market.

Pivot is also pleased to announce that Dr. Wolfgang Renz has been appointed as the Company’s Chief Medical Officer. Dr. Renz previously served as Corporate Vice President, Healthcare Innovation, at Boehringer Ingelheim. He also serves as Adjunct Professor of Surgery at McGill University’s Faculty of Medicine in Montreal. Dr. Renz holds a M.D. and Ph.D from Freiburg University and is board certified in Germany in Emergency Medicine.

“I am excited to lead the development of all medical and therapeutic activities from Pivot’s impressive bio-cannabis pipeline,” Dr. Renz said. “There is tremendous value and opportunity based on the numerous product formulation and dosing technologies Pivot has licensed or acquired over the past year. The technologies have demonstrated their usefulness in the pharmaceutical markets and delivering cannabinoids with these platforms will be disruptive.”

Dr. Patrick Frankham, Pivot’s CEO states, “The addition of a Dealer’s License for the Agro-Biotech facility will allow the Company to exercise complete control of our finished products, from seed to derivatives. With access to 10,000 kg of cannabis annually, the ability to extract, purify and formulate in-house, Pivot will provide the most exceptional quality, dosable products available on the market. This vertical integration makes Pivot a differentiated player in the cannabis industry.”

Dr. Frankham added that “the appointment of Dr. Renz provides Pivot with an experienced pharmaceutical executive who will accelerate the Company’s technological, marketing, sales and distribution partnerships in the European Union. We continue to aggressively execute on our business strategy.”

About Cannabis Compliance Inc.

Cannabis Compliance Inc. offers risk mitigation, due diligence and regulatory compliance for commercial cannabis producers and resellers around the world. We focus in the global market, and provide our clients with trusted and comprehensive solutions. CCI has extensive expertise in regulatory compliance, cultivation/horticulture, security designs/tender, facility designs/build-outs, quality assurance programs, import & export, staff recruitment and financial planning. CCI exists to empower the future leaders in the global cannabis industry. For more information please visit www.cannabiscomplianceinc.com.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.pivotpharma.com.

Cautionary Statement

Certain information in this news release constitutes forward-looking statements under applicable laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot, Pivot Green Stream, Agro-Biotech, or their respective management, identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to accretive earnings, anticipated revenue and costs synergies associated with the acquisition of Agro-Biotech, statements with respect to internal expectations, including with respect to the Dealer’s License, estimated margins, expectations for future growing capacity and costs, the completion of any capital project or expansions, the timing for the completion of the Proposed Transaction, the ability of the Company to complete a financing in order to satisfy its financial obligations under the Proposed Transaction and expectations with respect to future production costs. In particular, there can be no assurance that the Proposed Transaction will be completed. Forward looking statements are based on certain assumptions regarding Agro-Biotech, including expected growth, results of operations, performance, industry trends and growth opportunities. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; the possibility that the Company be unable to successfully integrate Agro-Biotech as described herein; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Any forward-looking statements or facts (including financial information) related to Agro-Biotech discussed or disclosed herein are derived from information obtained directly from Agro-Biotech and publicly available sources and has not been independently verified by the Company. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contact:

Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

The post Pivot Pharma Retains Cannabis Compliance to File Dealer’s License Application on Behalf of Agro-Biotech Inc. appeared first on CannabisFN.

Announcement of New Board Members, Introduction of CFO, and AGM Results

Toronto, Ontario–(Newsfile Corp. – March 9, 2018) – Luminor Medical Technologies (CSE: LMT), further to the acquisition of RISE Research Inc., announced today that it changed its corporate name to RISE Life Science Corp. which was approved at the Company’s annual and special shareholder meeting (the “Shareholder Meeting”) held on Tuesday February 27, 2018. The Company has reserved the stock symbol “RLSC” and will commence trading under this symbol upon approval by the Canadian Securities Commission.

“The name change reflects our emphasis on developing and evolving medical cannabis-based formulations to create general use health and well-being products for the emerging consumer category made possible by the legalization of cannabis.” said Anton Mattadeen, CEO, RISE Life Science Corp.

In addition, the Shareholder Meeting saw three new additions to the Board of Directors including Mr. Chris Dollard, Ms. Constance Finley and Mr. Michael Campbell.

Mr. Dollard is COO of RISE Life Science Corp.  Previously, he served as COO of RISE Research Inc. since its inception in the fall of 2015. He also brings to RISE Life Science Corp. a wealth of knowledge and experience from his work related to operational planning and facility design pertaining to early cannabis producer applications. Before entering the cannabis industry in late 2012, Mr. Dollard built a 25+ year career in the information technology industry with Fortune 500 companies such as Deloitte, Accenture, IBM and Best Buy, as well as many smaller firms and startups.

Ms. Finley is the founder and President of Constance Therapeutics, a San Francisco-based company that produces whole plant medicinal cannabis extracts for physicians and their patients. She is recognized as an industry leader and is a frequent speaker at leading industry conferences including CannaTech, SXSW, The California Academy of Sciences, the Cure Cancer Now Summit, CWCBExpo, and the Cannabis Quality Strategies and Solutions Summit.  She sits on various advisory boards, including an assignment to the Scientific Advisory Board for CannaTech.

Mr. Campbell is General Counsel and Corporate Secretary of Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled and targeted release oral solid dosage drugs. He previously served as General Counsel for Griffis Capital and Canada Cartage System L.P.

It was also announced that Mr. Harry Bloomfield, who has served as Chairperson of Luminor Medical Technologies Board of Directors, has retired from the Board. Anton Mattadeen has been elected as Chairperson of the Board of Directors.

“Mr. Bloomfield’s insights during his tenure as Chairman, helped to significantly move the company forward.” said Anton Mattadeen. “We wish to thank him for his leadership.”

RISE Life Science Corp. is pleased to announce that Robert Lelovic CPA, CA has joined the company as Chief Financial Officer. Mr. Lelovic replaces Chris Carmichael who has filled this role during the transition period from Luminor to RISE Life Science Corp. Mr. Lelovic graduated from York University in 1998 and has been a chartered accountant since 2001. He has extensive experience in public company reporting, corporate governance and compliance. Mr. Lelovic is the president of Robert Lelovic Professional Corporation, a company registered with the Institute of CPA Ontario and the co-founder of Inlync.

“We would also like to offer our sincere thanks to Chris Carmichael for his invaluable input into the creation of the company structure,” said Anton Mattadeen. “And look forward to working with him in the future.”

Finally, additional resolutions approved at the Shareholder Meeting included the appointment of MNP LLP as auditor, re-approval of the Company’s stock option plan, change of registered address to 145 King Street West, Suite 210, Toronto, ON M5H 1J8 and the reduction of paid up capital in connection with a reorganization of the Corporation involving the distribution of all of the Corporation’s shares of its wholly owned subsidiary Scout Assessment Corp. (the “Scout Corp Distribution”) to the Corporation’s shareholders. The Scout Corp. Distribution is subject to a number of conditions including the filing of a prospectus with the Ontario Securities Commission, CSE approval and approval by the Directors of the Company. Further details of the resolutions can be found on the management information circular filed on www.sedar.com on February 7, 2018.

For more information, please contact:
Mark Komonoski
mark@komonoski.com
877-255-8483
403-470-8384

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Luminor’s (now RISE) periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward- looking statements. Forward-looking statements may include, without limitation, statements including the Company’s expectations with respect to pursuing new opportunities and its future growth and other statements of fact.

Although RISE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US Federal Laws; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change. There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. RISE disclaims any intention or obligation to update or revise such information, except as required by applicable law, and RISE does not assume any liability for disclosure relating to any other company mentioned herein.

The post Luminor Medical Technologies Changes Its Name to RISE Life Science Corp. appeared first on CannabisFN.